Tenaya Therapeutics Inc (TNYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $79.59M
Last updated: Nov 17, 2026 at 4:15 PM ET
Tenaya Therapeutics Inc (TNYA) Statistics
Tenaya Therapeutics (TNYA) has a market cap of $79.59M and an enterprise value of $12.80M. It kept -3356.79% of revenue as net income over the last 12 months. Its share count is up 38.36% from a year earlier.
Total Valuation
Enterprise value is 83.92% below the market cap, as cash exceeds debt.
| Market Cap | $79.59M |
|---|---|
| Enterprise Value | $12.80M |
| Latest price (Nov 17, 2026) | $0.32 |
Key Dates
The next earnings report is expected on Mar 4, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 4, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| Forward P/S | 20.7x |
|---|---|
| P/B Ratio | 1.3x |
Price Statistics
The stock is down 75.73% over 52 weeks and trades 34.69% below its 50-day average.
| Beta (1Y) | 2.70 |
|---|---|
| 52-Week Change | -75.73% |
| 1-Month Change | -14.51% |
| 3-Month Change | -54.72% |
| 6-Month Change | -59.01% |
| 5-Year Change | -98.57% |
| Total Return (1Y) | -75.73% |
| Total Return (3Y CAGR) | -44.41% |
| Total Return (5Y CAGR) | -56.75% |
| Max Drawdown (1Y) | -77.59% |
| Max Drawdown (3Y) | -95.35% |
| Sharpe Ratio (1Y) | -1.36 |
| Correlation with SPY (1Y) | 0.37 |
| 50-Day Average | $0.49 |
| 200-Day Average | $0.69 |
| 52-Week Range | $0.30 to $1.46 |
| RSI (14 Days) | 33.1 |
| Average Volume (20 Days) | 2.49M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.78x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.78x |
|---|---|
| Quick Ratio | 3.78x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| ROE (5Y Average) | -71.82% |
|---|---|
| ROA (5Y Average) | -58.91% |
| Asset Turnover | 0.03x |
Scores
TNYA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $3.03M over the last 12 months.
| Revenue | $3.03M |
|---|---|
| Gross Profit | $6.98M |
| Operating Income | -$104.50M |
| Pretax Income | -$101.78M |
| Net Income | -$101.78M |
| EBITDA | -$98.22M |
| Reported EPS (TTM) | -$0.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 71.10% of the $76.68M in total assets.
| Cash and Equivalents | $66.80M |
|---|---|
| Total Debt | $0 |
| Net Cash | $66.80M |
| Net Cash Per Share | $0.30 |
| Working Capital | $52.21M |
| Shareholder Equity | $54.52M |
| Book Value Per Share | $0.24 |
| Total Assets | $76.68M |
| Total Liabilities | $22.16M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$54.41M |
|---|---|
| FCF Per Share | -$0.24 |
| Depreciation and Amortization | $5.65M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -3446.57%.
| Gross Margin | 230.21% |
|---|---|
| Operating Margin | -3446.57% |
| Pretax Margin | -3356.79% |
| Net Margin | -3356.79% |
| EBITDA Margin | -3239.48% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -37.16% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -37.16% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TNYA
What is TNYA's market cap?
Tenaya Therapeutics has a market cap of $79.59M. Its enterprise value, which adds debt and subtracts cash, is $12.80M.
How many shares of TNYA are outstanding?
Tenaya Therapeutics has 226.01M shares outstanding. The count is up 38.36% from a year earlier.
Does TNYA pay a dividend?
No. Tenaya Therapeutics does not pay a dividend.
How much debt does TNYA have?
Tenaya Therapeutics has $0 of total debt and $66.80M of cash and equivalents, a net cash position of $66.80M.
TNYA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors